STEMCELL-TECHNOLOGIES
26.3.2024 13:01:28 CET | Business Wire | Press release
STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240326396951/en/
STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit is now classified by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment. (Photo: Business Wire)
The kit can be used to enrich plasma cells expressing the CD138 marker (CD138+ cells) from patient bone marrow samples. Such cell-type-specific enrichment can increase the sensitivity of downstream in vitro diagnostic tests for multiple myeloma—a cancer of plasma cells—to better inform patient risk and course of treatment. Accounting for approximately 2% of all cancers in the United States1, multiple myeloma is incurable, and variable or low frequencies of CD138+ cells in bone marrow samples can impact the reliability of detecting genetic abnormalities that influence the disease’s progression. Incorporation of STEMCELL's new kit in a pre-analytical step of the diagnostic workflow can contribute to improving patient care and outcomes by enhancing the sensitivity and resolution of these downstream assays.
“STEMCELL is proud to develop the first hematopoietic cell enrichment product identified as an in vitro diagnostic device by the FDA,” said Dr. Allen Eaves, President and CEO, STEMCELL. “Creating an IVD product that improves the accuracy of information guiding the treatment of patients with multiple myeloma is a milestone achievement that reflects our commitment to make a positive impact on human health.”
The FDA identifies this new product type as a hematopoietic cell enrichment kit: a Class II IVD device for selecting specific cells from human whole blood or bone marrow, intended for use with diagnostic assays as part of the pre-analytical workflow. Agencies such as the National Comprehensive Cancer Network and the American College of Medical Genetics recommend CD138+ cell enrichment upstream of fluorescence in situ hybridization (FISH) testing for multiple myeloma; however, until now, hematopoietic cell enrichment products have not been classified as IVD devices by the FDA.
“This De Novo classification will have a permanent impact on the IVD landscape and paves the way for further innovation,” said Dr. Eaves. “STEMCELL is committed to building on this foundational work in the IVD field with novel diagnostic products and support, including supporting industry partnerships through our Diagnostics Partnerships and OEM Solutions Program.”
The EasySep™ Human Bone Marrow CD138 Positive Selection Kit is part of STEMCELL’s portfolio of EasySep™ immunomagnetic cell isolation technologies, specifically developed for fast and easy isolation of highly purified cells that are ready for downstream applications. It marks the culmination of many years of work, which included examining more than 230 bone marrow aspirates from multiple myeloma patients, precision studies of inter- and intra-laboratory reproducibility, and limit of detection and interference studies. The EasySep™ Human Bone Marrow CD138 Positive Selection Kit will be available for sale in the United States, the European Union, Canada, and the United Kingdom.
1Padala et al. 2021 Med Sci (Basel)
About STEMCELL Technologies
STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326396951/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
HyperLight Introduces 145 GHz Reference Modulators to Enable 448Gbps per Lane Datacom and 260GBaud Telecom Development12.3.2026 14:03:00 CET | Press release
HyperLight Corporation, creator of the TFLN Chiplet™ platform, today announced the release of its 145 GHz Packaged Intensity Modulator (IM), expanding the company‘s high-speed modulator portfolio. The new device is designed for ultra-wide modulation bandwidth, high signal fidelity, and stable operation control, enabling 448 Gbps per lane intensity-modulated-direct-detection (IMDD), 260 GBaud coherent links, and broadband RF photonics systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312319685/en/ Fig. 1: HyperLight’s 145 GHz intensity modulator for 448Gbps per lane IMDD and 260GBaud coherent applications, with operational electro-optical bandwidth >145GHz, stable bias control, 0.8 mm-connector; available in O-, C-, and L-bands. As symbol rates and analog bandwidth requirements continue to rise across data center interconnects, AI-driven photonics infrastructure, and laboratory test environments, system architects in
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences12.3.2026 14:00:00 CET | Press release
Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. The acquisition enables Enodia to advance its understanding of Sec61 selectivity mechanisms, expanding biological and translational insights for faster progression toward key clinical milestones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312627573/en/ Under the terms of the purchase agreement between Enodia and Kezar, Kezar w
Adtran to showcase industry-leading open optical networking for the AI era at OFC 202612.3.2026 14:00:00 CET | Press release
News summary: Adtran will show how intelligent optical networks can scale infrastructure while controlling power, complexity and security risks Highlights include LiteWave800™, an ultra‑low‑power 800G pluggable transceiver, which sets a new 1pJ/bit benchmark for intra‑data center connectivity Adtran will participate in OIF multi‑vendor interoperability demos and present European‑led innovation through advanced research projects Adtran today announced that it will showcase its latest optical innovations at OFC 2026, taking place from March 15 to 19 in Los Angeles. The company will outline how intelligent, secure and power‑efficient optical networks are shaping the next phase of AI infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311958018/en/ Adtran’s optical networking technology is helping build the foundation for the AI era. At Adtran’s booth (1001), visitors can explore solutions spanning ultra‑low‑power
Wellesley Hills Financial Goes Global: New London and New York Hubs Signal Aggressive Expansion into Transatlantic Fintech M&A12.3.2026 13:00:00 CET | Press release
With the addition of industry veterans Barry Davis and Bill Shraga, WHF strengthens its cross-border capabilities and scales its specialized Merchant Portfolios platform to a national level. Wellesley Hills Financial (“WHF”), a premier fintech and payments-focused investment bank spanning the lower to upper middle market, today announced a series of senior appointments and geographic expansions that further scale its global advisory platform and deepens its capabilities across the payments and fintech ecosystems. The firm has appointed Barry Davis as Executive Advisor, based in London, added Managing Director Bill Shraga in New York, and expanded its payments consulting subsidiary, Merchant Portfolios (“MP”), with the addition of EVPs Lance McCord in North Carolina and Nolan Pittman in Arizona. Strengthening Transatlantic Connectivity Barry Davis joins WHF as the firm’s first London-based Executive Advisor, marking a significant milestone in WHF’s international expansion. His appointme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom